Studies in rodents suggest that flumazenil is a P-glycoprotein substrate at the blood-brain barrier. This study aimed to assess whether [ 11 C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [
Introduction
Flumazenil binds to the gamma-aminobutyric acid A (GABA A ) receptor, but has no agonistic or antagonistic actions on this receptor. The positron emission tomography (PET) radioligand [ 11 C]flumazenil is used widely for assessing changes in GABA A receptor density and to assist in determining the site of seizure onset prior to resective surgery in medically refractory epilepsy patients. 1, 2 Recent ex vivo and in vivo data, however, suggest that [ 11 C]flumazenil is a P-gp substrate in rodents. [3] [4] [5] It has been hypothesized that P-glycoprotein (P-gp) is upregulated in areas with epileptic activity. 6 If [ 11 C]flumazenil is indeed a P-gp substrate in humans, upregulation of P-gp at the blood-brain barrier (BBB) due to epilepsy could lead to reduced cerebral uptake of [ 11 C]flumazenil, and thus to erroneous interpretation of GABA A receptor density changes.
The impact of P-gp on cerebral uptake of [ 11 C]flumazenil can be investigated by pharmacological inhibition of P-gp with tariquidar. This compound is one of the most effective P-gp inhibitors, binding to P-gp with high selectivity and affinity. [7] [8] [9] The purpose of the present study was to assess whether [ 11 C]flumazenil is a P-gp substrate in humans and, if so, to what extent changes in cerebral [ 11 C]flumazenil uptake in drug-resistant patients are due to changes in P-gp activity rather than GABA A receptor density. To address these issues, scans were performed in drug-resistant patients with temporal lobe epilepsy (TLE) and evidence of unilateral mesial temporal sclerosis (MTS) on magnetic resonance imaging (MRI). This syndrome with partial seizures is one of the most prevalent and refractory types of epilepsy with only 20% of patients achieving seizure freedom on medication. [10] [11] [12] Seizures often originate in the areas identified on MRI, have a highly characteristic videoelectroencephalography (EEG) pattern, both in terms of ictal rhythms and with respect to the ictal semiology. 13 These areas may show stronger increase in P-gp activity than other brain regions and thereby present a suitable target to test the proposed hypothesis.
Materials and methods Participants
Eleven drug-resistant patients with TLE and unilateral MTS between 18 and 60 years of age were recruited from the outpatient clinics of the tertiary referral centre for epilepsy patients Stichting Epilepsie Instellingen Nederland (SEIN). Diagnosis of TLE and unilateral MTS was based on clinical evaluation, EEG, and MRI. All subjects underwent standard screening, including medical history, physical and neurological examination, screening laboratory tests, and brain MRI to exclude serious medical conditions, psychiatric illness, drug abuse, and coagulation problems. Patients with MRI abnormalities other than those suggesting presence of MTS, white matter changes, or an incidental small lacunar lesion were excluded. Other exclusion criteria were use of benzodiazepines, non-steroidal anti-inflammatory drugs, antithrombotics, acetylsalicylic acid, or drugs known to interfere with P-gp, [14] [15] [16] other than antiepileptic drugs. Written informed consent was obtained from each participant. The study was approved by the Medical Ethics Review Committees of VU University Medical Center and SEIN.
MRI
All patients underwent a structural MRI scan using a 3T scanner (Signa HDXt, General Electric, Milwaukee, USA) according to a fixed protocol, including T1-weighted 3D magnetization-prepared rapid acquisition gradient echo (MPRAGE) covering the whole brain, T2-weighted axial fluid-attenuated inversion recovery images, and T2 axial images. The coronal T1-weighted MPRAGE sequence was used for coregistration with the PET scan and for region of interest (ROI) definition.
PET data acquisition
All patients underwent two identical PET scans on the same day. Scans were performed on an ECAT EXACT HRþ scanner 17 (Siemens/CTI, Knoxville, USA), which enables acquisition of 63 transaxial planes of data over a 15.5 cm axial field of view, thus allowing the whole brain to be imaged in a single bed position. To minimize movement artifacts, the head was immobilized and, using laser beams, its position checked for movement during scanning. All patients received an indwelling radial artery cannula for blood sampling and a venous cannula for tracer administration. During the entire PET scanning day, patients were monitored using EEG and video to identify possible ictal events. Subsequently, video-EEG recordings were reviewed by two qualified neurophysiologists with experience in EEG-CCTV seizure monitoring (DNV and JZ). Before tracer injection, a 10-minute transmission scan was performed in 2D acquisition mode using three retractable rotating line sources. This scan was used to correct the subsequent emission scan for photon attenuation. After the transmission scan, a dynamic emission scan in 3D acquisition mode was started simultaneously with an intravenous injection of about 370 MBq [ 11 C]flumazenil by means of an infusion pump (Med-Rad, Beek, the Netherlands; injection rate 0.8 mLÁs À1 followed by a flush of 35 mL saline at 2.0 mLÁs À1 ). The emission scan consisted of 16 frames with increasing frame duration (4 Â 15, 4 Â 60, 2 Â 150, 2 Â 300, 4 Â 600 s) with a total duration of 60 minutes. Using an online blood sampler (Veenstra Instruments, Joure, the Netherlands), arterial blood was withdrawn continuously at a rate of 5 mLÁmin À1 for the first 5 min and 2.5 mLÁmin À1 , thereafter until 30 minutes after tracer injection. Continuous withdrawal was briefly interrupted at 2.5, 5, 10, 20, and 30 minutes post tracer injection (p.i.) for collection of 10 mL manual blood samples. At 40 and 60 minutes p.i., additional 10 mL blood samples were obtained from the arterial cannula. Blood samples were used to calibrate the online blood sampler curve, and to measure plasma to whole blood radioactivity concentrations and parent [ 11 C]flumazenil fractions in plasma, enabling generation of a metabolite-corrected plasma input curve. The last 30 minutes of the input curve, when there was no continuous blood sampling, were extrapolated using the manual samples collected at 40 and 60 minutes. After a resting period of at least 3 hours to allow for decay of carbon-11, the scanning procedure was repeated, but this time after tariquidar administration at a dose of 2 mgÁkg À1 body weight administered as a 30 minutes intravenous infusion 110 minutes prior to the [ 
PET data analysis
All PET sinograms were corrected for dead time, scatter, randoms, decay, and tissue attenuation, and were reconstructed with a standard filtered back-projection algorithm, using an image matrix size of 256 Â 256 Â 63, resulting in voxel sizes of 1.2 Â 1.2 Â 2.4 mm. After reconstruction a transaxial spatial resolution of $7 mm in the center of the field of view was obtained. Further data processing was performed using noncommercial software packages. The sum of all PET images was coregistered with the MRI image using Vinci software. 18 Thereafter, obtained transformation coefficients were applied to all PET frames, resulting in dynamic PET and MRI scans having the same orientation. ROIs were defined using PVElab, a software program that utilizes a previously validated probability map of 38 delineated grey matter ROIs. 19 In addition, an attempt was made to identify, in each patient, a region of decreased Template ROI data were analyzed using two complementary methods, a single-tissue compartment (1TC) model, and the simplified reference tissue model (SRTM). 20 Typically, interpretation of the volume of distribution (V T ) as an index of receptorbinding density assumes that differences in V T estimates (V ND þ V S ) are due to differences in specific binding (V S ) and not to those in the nondisplaceable volume of distribution (V ND ¼ K 1 /k 2 ). Similarly, estimates of the nondisplaceable binding potential (BP ND ) from SRTM assume that K 1 /k 2 (V ND ) is constant across the brain. By combining both analyses, it is possible to look for changes in the ratio of the rate constants for [
11 C]flumazenil transport across the BBB (K 1 /k 2 ), and hence [
11 C]flumazenil efflux (k 2 ) across the BBB, with sufficient estimation to enable investigation of potential P-gp effects. For this purpose, first, V T and the rate constant K 1 were obtained using a 1TC model with metabolite-corrected plasma input function and blood volume as a fitting parameter. 20 V T represents the ratio of flumazenil concentrations in tissue and (metabolite-corrected) plasma under equilibrium conditions. Next, BP ND was determined using the SRTM with pons as reference tissue. 20 To this end, the pons was manually segmented on the MRI image and then projected onto the coregistered dynamic PET data. In order to reduce variability, the pons was delineated once and used for both (coregistered) PET scans. BP ND represents the ratio of GABA A receptor association over dissociation constants (k 3 /k 4 ) of flumazenil. In terms of a twotissue compartment (2TC) model, V T corresponds to K 1 /k 2 Á(1 þ BP ND ). Consequently, the ratio of the rate constants for [ 11 C]flumazenil transport across the BBB (K 1 /k 2 ) was calculated as V T /(1 þ BP ND ). Finally, to explore whether tariquidar has an effect on [ 11 C]flumazenil influx (K 1 ) or efflux (k 2 ) across the BBB, k 2 was calculated as K 1 divided by K 1 /k 2 . As the approach mentioned above is an indirect way to obtain K 1 /k 2 , data were also analyzed using a reversible 2TC model. 20 For each patient both ROIs were projected onto the dynamic PET scans and values of BP ND , V T , K 1 /k 2, K 1 , and k 2 were obtained as described above. Regional analyses were performed with all regions in the hemisphere where evidence of unilateral MTS on MRI was found at one side. This side was called ipsilateral, and all corresponding regions in the other hemisphere were named contralateral.
Statistical analysis
First, in order to test whether [ 11 C]flumazenil is a P-gp substrate, differences in whole brain values of V T , BP ND , K 1 /k 2 , K 1 , and k 2 between pre-and post-tariquidar scans were evaluated using nonparametric Wilcoxon signed-rank tests. For further exploration, regional values of the significant parameters of the whole brain analyses as well as pons V T , K 1 , and k 2 (1TC model) were compared between pre-and post-tariquidar scans. Second, baseline regional values of V T , BP ND , and K 1 /k 2 from standard ROIs at the side of MTS were compared to corresponding contralateral ROIs. Third, baseline values of V T , BP ND , and K 1 /k 2 from the manually defined epileptic foci were compared with corresponding regions on the contralateral side. p < 0.05 was considered significant.
Spearman's rank-order correlation test was used to assess a correlation between tariquidar plasma concentration levels and V T , K 1 /k 2 , and k 2 changes in response to tariquidar. Finally, the nonparametric Wilcoxon signedrank test was used to assess whether there were significant differences between baseline and posttariquidar values of injected dose, specific activity, fraction of radio-labeled plasma metabolites, and plasma radioactivity concentrations. For all tests p < 0.05 was considered significant, except for the latter 2 for which Bonferroni correction for multiple (i.e., 7) comparisons was necessary (p < 0.007 was considered significant). Data are presented as mean AE standard deviation (SD) unless stated otherwise.
Results

[
11 C]flumazenil scans were performed in 11 patients with TLE and unilateral MTS. Due to technical problems with the online blood sampler in one patient and occlusion of the arterial line in another, scans from nine patients could be analyzed. Table 1 shows patient and scan characteristics. Three patients experienced events on the scanning day. One patient (subject 1) experienced a complex partial seizure approximately 90 minutes after tariquidar administration, which was documented on the video-EEG registration. The second patient (subject 3) was temporarily unresponsive, but it was not clear whether this was caused by epileptic activity, as no electrographical abnormalities were observed at that time. Afterwards she was disorientated for a short while and experienced a headache. The third patient (subject 4 Table 3 ).
Using the same models for assessment of baseline differences between the ipsi-and contralateral ROIs, regional analyses revealed significantly lower V T and BP ND in ipsilateral hippocampus (À18%, p ¼ 0.008 and À20%, p ¼ 0.008, respectively), amygdala (À15%, p ¼ 0.012 and À17%, p ¼ 0.012, respectively), and medial inferior temporal gyrus (À4%, p ¼ 0.020 and À5%, p ¼ 0.020, respectively) as compared with the contralateral side. In all other ROIs no significant left-right differences were observed. In addition, significantly lower K 1 /k 2 ratios in ipsilateral hippocampus (p ¼ 0.008), superior temporal gyrus (p ¼ 0.039) and thalamus (p ¼ 0.039) were found, as compared with the contralateral side, although these differences were not substantial (namely betweenÀ0.4 and À2%). In only three patients a region of decreased cerebral [ 11 C]flumazenil uptake could be identified by visual inspection. V T and BP ND were significantly lower in these regions than in the corresponding contralateral ROIs, whereas no differences in K 1 /k 2 between regions were observed (Table 4 ).
In the reanalysis using the 2TC model, one patient (subject 4) had to be excluded because only 40 minutes of the posttariquidar scan data were available, resulting in unreliable fits. In the remaining eight patients, whole brain V T was 5.69 AE 0.71 and 5.96 AE 0.70 for pre-and post-tariquidar scans, respectively. These values were comparable with those obtained using the 1TC model, but for the 2TC model the difference in V T between preand post-tariquidar scans was not significant (p ¼ 0.20). It was not possible to fit regional data reliably using the 2TC model, as too many results had to be rejected because of nonphysiological parameter estimates with high standard errors.
Discussion
The main finding of this study was an increase of 23% in the K 1 /k 2 ratio of [
11 C]flumazenil after partial P-gp blockade. As these rate constants are related to transport of [ 11 C]flumazenil across the BBB, this finding supports the notion that [
11 C]flumazenil is indeed a P-gp substrate, as demonstrated previously in in vivo studies in rodents using both a genetic disruption model and the same pharmacological inhibition model. 3, 21 It is also in line with results from an ex vivo study in mice. 4 On the other hand, the comparison between assumed site of seizure onset and contralateral side did not show differences in K 1 /k 2 , and therefore does not provide evidence that P-gp activity is altered at the site of seizure onset in TLE patients. Interestingly, regional analyses showed substantially lower V T and BP ND in hippocampus and amygdala at the ipsilateral side, but no corresponding change in K 1 /k 2 . This suggests that the reduction in [ 11 C]flumazenil uptake exclusively reflects a decrease in GABA A receptor density due to epileptic activity in these regions.
In theory, the increase in K 1 /k 2 after partial P-gp blockade could be due to either increased influx (K 1 ) of [ ]flumazenil is a substrate of P-gp, administration of tariquidar, which results in P-gp inhibition, should lead to decreased efflux (k 2 ) rather than influx (K 1 ). 21 The present study confirmed that k 2 rather than K 1 was affected by tariquidar. The finding that V T was significantly affected by tariquidar, though to a lesser extent than K 1 /k 2 , is also in line with previous findings, as the brain-to-plasma ratio is expected to increase due to tariquidar. In addition, as pons is almost devoid of GABA A receptors, the significant increase of 17% in pons V T (1TC model) after P-gp inhibition also suggests that [ 11 C]flumazenil is a P-gp substrate. Altogether, these results are in line with the notion that flumazenil is a P-gp substrate in humans. In addition, BP ND was not affected significantly by P-gp inhibition, which is also in line with animal studies showing that tariquidar had no effect on [ 11 C]flumazenil binding to the GABA A receptor in both naı¨ve and kainate-treated rats. 21 Previous in vitro transport assay studies have reported that flumazenil is not transported by human P-gp, 22, 23 which is in contrast with findings of previous in vivo rodent studies and the present study. These differences have been attributed to species differences in BBB transport of [ 11 C]flumazenil, a phenomenon that has also been observed for other PET radioligands. 24 It is more likely, however, that these contradicting results are due to the lower sensitivity of in vitro assays for detecting weak to moderate P-gp substrates. There may be several reasons for the difference in degree of inhibition of flumazenil transport across the BBB after P-gp blockade with tariquidar in humans (23%) than in rodents ($70%). First, in the in vivo rodent studies full P-gp blockade was obtained, 3 whereas this was not possible in the present study in humans, 25 as it was considered unsafe to administer higher tariquidar doses than 2 mgÁkg À1 body weight 25 to patients who also use antiepileptic drugs. Second, species differences in BBB transport of several P-gp substrates have shown a more pronounced increase in cerebral uptake of these substrates after P-gp inhibition in rats than in higher species. 24 The finding that GABA A receptor density is focally altered due to epilepsy is in line with earlier studies. 5, 21, 26 However, the fact that no evidence for locally altered P-gp function was found needs further consideration. Perhaps flumazenil is too weak a P-gp substrate to detect regional alterations in P-gp function. Previous studies on resected brain tissue of refractory epilepsy patients, animal studies and an in vivo PET study with the P-gp substrate tracer (R)-[ 11 C]verapamil in humans have shown that both P-gp overexpression and P-gp upregulation play a role in drug resistance in epilepsy. 6, 27 However, direct clinical proof for P-gp upregulation is scarce. Therefore, more human PET studies with both P-gp substrate and P-gp inhibitor tracers are needed to provide further insight into the presence and, if so, clinical relevance of altered P-gp functionality and expression in drug resistance in epilepsy. As 25, 28 presence and severity of P-gp upregulation can better be assessed using one of those tracers.
The principle analysis used in the current study was based on the combined use of 1TC and SRTM models. Ideally, results should be derived from a single model and, in theory, all kinetic parameters can be obtained using a reversible 2TC model. Unfortunately, the latter model did not provide reliable estimates of individual rate constants and BP ND , which is in line with a previous study showing that distinguishing the two compartments from each other is quite difficult, especially for higher noise levels (small ROIs). 29 Nevertheless, the similarity of whole brain V T values derived from 1TC and 2TC models, which is in agreement with previous studies, 20, 29 indicates that possible bias by lumping the two compartments together in the 1TC model is small. Interestingly, the difference in whole brain V T between pre-and post-tariquidar scans was significant for the 1TC, but not for the 2TC model. This probably also is due to increasing uncertainty in parameter estimates with increasing number of parameters.
The finding that no correlation was found between tariquidar plasma concentration levels and changes in V T , K 1 /k 2 , and k 2 in response to tariquidar probably is due to the fact that flumazenil is only a weak P-gp substrate.
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